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Preface 
In the context of discussions around the draft European Union chemical law, ‘REACH’, the World 
Wide Fund For Nature, (WWF Toxics Programme), in cooperation with the Co-Operative Bank, 
decided to bring attention to the exposure of humans (and wildlife) to persistent, 
bioaccumulative and endocrine disruptive chemicals by organizing a “Chemicals Check-Up”. At 
least 40 European members of parliament participated by donating blood in December 2003. 
This blood was analysed by several labs in Europe for a variety of chemicals (ca. 70) in order to 
illustrate the level of environmental contamination that can be expected in European citizens. 
The laboratory of the Netherlands Institute for Fisheries Research contributed to the WWF 
initiative by analysing samples for the brominated flame retardants (BFRs) 
hexabromocyclododecane (HBCD) and tetrabromobisphenyl-A (TBBP-A) in the blood samples. 
The results of this study are presented in this report. 
  
 
Summary 
The brominated flame retardants, hexabromocyclododecane (HBCD) and tetrabromobisphenyl-A 
(TBBP-A) were analysed in samples of human blood from 40 different individuals. In only one 
individual was HBCD detected. In about half of the individuals, TBBP-A was detected. When they 
were detected, the amounts of both chemicals were near the limits of quantification. That the 
chemicals were detected confirms that certain individuals were exposed to sources of these 
substances. The toxicological implications of these low levels are not well known. Very few 
studies of the toxicology of these compounds have been performed to date. 
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1. Introduction 
Brominated flame retardants (BFRs) such as hexabromocyclododecane (HBCD) and particularly 
tetrabromobisphenyl-A (TBBP-A) are widely used in Europe and elsewhere in such products as 
polystyrene foams, upholstery textiles and electronic equipment [de Wit 2002]. While flame 
retardants are highly important for their fire-retardant properties, they also have disadvantages. 
They can escape during production processes or from the finished products and be emitted to 
the environment. The emissions become distributed among the different environmental 
compartments (e.g. air, sediments, biota, water).  
Due to their physical-chemical properties, these compounds are rather poorly soluble in water 
but have a high affinity for organic matter, lipids and biological tissues. These kinds of 
chemicals have already been detected in marine and freshwater sediments, in wastewater 
treatment plants and landfill leachates but also in aquatic biota, birds, mammals, including 
human serum and mothers’ milk [e.g. Wantanabe et al. 1983; Sellström et al. 1998; de Boer et 
al. 2002a; Thomsen et al. 2001, 2002, 2003; Jacobsson et al. 2002; Sellström et al. 2003; 
Zegers et al. 2003; Tomy et al. 2003]. Studies on the distribution, behaviour and toxicity of 
TBBP-A and in particular, HBCD are limited in number [de Wit 2002]. Blood is a common sample 
type for the assessment of human exposure because compounds are more often present in a 
non-metabolised form than in urine, for example. While TBBP-A has been detected in human 
plasma [Klasson Wehler et al. 1997; Thomsen et al. 2001] and serum [Thomsen et al. 2002; 
Jacobsson et al. 2002] to date, no published data on HBCD concentrations in blood exist to our 
knowledge.  
The objective of this present study was to analyse concentrations of hexabromocyclododecane 
(HBCD) and tetrabromobisphenol-A (TBBP-A) in human blood samples. 
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2. Chemical structures of analytes  
Tetrabromobisphenol-A 
TBBP-A is a phenolic BFR (Figure 1). Because it is ionic, it can be protonated or deprotonated 
depending on the pH. This can affect its ability to interact or react with other molecules such as 
organic material in sediments or biological macromolecules in living organisms. TBBP-A has a 
high octanol-water partition coefficient, (log Kow 5.9) and is more soluble under acidic conditions 
(low pH) than when the medium is alkaline. At a pH of 7.4, such as in human blood, TBBP-A can 
be expected to be partially deprotonated and susceptible to interactions with proteins and other 
macromolecules in the blood. 
 
 
 
 
Hexabromocyclododecane 
Three diastereomers of HBCD, ? -, ? - and ?-HBCD (Figure 2) can be identified. Assays of isomer 
distribution in a number of different samples of commercial HBCD, [Peled et al. 1995] showed 
the technical mixture of HBCD to be predominantly composed of ?-HBCD (ca. 76%), while ? - and 
? -HBCD made up about 13% and 11% respectively. Studies to date indicate that the patterns of 
bioaccumulation in organisms tend to be different than the composition of technical mixture 
would suggest, with a relatively large contribution of ? -HBCD to the total HBCD body residue 
being found to date [de Boer et al. 2002a].  
Analysis by gas chromatography (GC) leads to changes in the isomeric ratio of HBCD at the 
high temperatures (>160°C) in the gas chromatograph, although total HBCD concentrations are 
still measurable by GC/MS [Covaci et al. 2003]. International laboratory studies have shown that 
only a few laboratories worldwide are able to carry out reliable GC/MS and LC/MS analyses of 
HBCD [de Boer et al. 2002b]. The different HBCD isomers can be separated and quantified 
using LC/MS. However, this method requires relatively high concentrations of analyte compared 
to the GC/MS method. Because of the analytical challenges, diasteromer-specific concentration 
data for environmental matrices or human tissues are currently very limited.  
  
 
Figure 1. Chemical structure of 
tetrabromobisphenol-A. 
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? -HBCD ? -HBCD 
?  -HBCD 
Figure 2. Structures of hexabromo-
cyclododecane diastereomers, ? -
HBCD (1R,2R,5S, 6R,9R,10S), ? -
HBCD (1S,2S,5R, 6S,9R,10S) and ?-
HBCD (1R,2R, 5R,6S,9S,10R). Black 
circles indicate that the Br-atom is 
positioned into the plane of the paper, 
open circles indicate Br is positioned 
out of the plane of the paper [from 
Peled et al. 1995]. 
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3. Materials and Methods 
Human blood of 46 individuals was drawn in Brussels on 2 and 3 December 2003, and 
collected in either glass (SST) or plastic (SST-II) BD Vacutainer vials. Blood was sent (frozen and 
on dry ice) to the Netherlands. Forty samples with the highest sample volumes were analysed 
for HBCD and TBBP-A. The method of extraction, clean up and chemical analysis is based on a 
standardized procedure for measuring flame retardants in biota [Hesselingen and Brandsma, 
2003] of the Netherlands Institute for Fisheries Research.  
 
Soxhlet extraction, GPC and GC-MS analysis 
Blood samples (excluding the silica gel contents of the vacutainer vials) were weighed and dried 
by mixing with sodium sulphate and then extracted by Soxhlet extraction with hexane:aceton as 
solvent. Following Soxhlet, internal recovery standards were added to the blood extracts. For 
TBBP-A the internal standard was 13C-TBBP-A, for HBCD, BDE116 was used. To ensure that 
TBBP-A was in the protonated form and retained in the organic phase before proceeding with 
the next steps, the Soxhlet extract was treated with a sulphuric acid solution (pH 2).  
 
Extracts were then purified with the gel permeation chromatography (GPC) technique to remove 
large biomolecules such as lipids before injecting into analytical apparatus, as these would 
interfere with the analysis. The organic layer was further cleaned with silica gel to remove other 
matrix compounds. Finally, the purified extracts were transferred to vials for analysis with 
GC/MS.  
 
TBBP-A and HBCD in blood extracts were measured by gas chromatography/mass 
spectrometry (GC/MS) in four series. Each series included two blanks, an internal reference 
material sample (eel), and a recovery standard. Due to limitations of the blood sample volume, 
no duplicate extraction of a blood sample was performed. Quantification was performed using 
external standards. Final concentrations were corrected for percent recovery determined by 
recovery standards. No LC-MS analysis of the extracts was performed because TBBP-A was 
analysed with GC-MS, and HBCD concentrations were too low to detect the separate HBCD 
diastereomers in an LC-MS chromatogram. 
 
  
 
Page 8 of 13 RIVO report C009/04 
 
 
 
 
4. Results  
TBBP-A was detected in about half of the blood samples in the ng/kg blood range (see 
Appendix). In the other blood samples, no TBBP-A was detected. The concentrations in the 
blood extracts were reported if the measured concentration was ?5 times higher than the blank 
signal. If the value was ?3 times higher than the blank signal it was reported with an indication 
of this. All extracts had concentrations below the lowest standard, but since the peaks in the 
chromatograms could be detected and integrated, these values were not reported as ‘under 
detection limit’ in this case. Normally these concentrations would be reported as <L.O.D. so it 
must be stressed that this lends uncertainty to the reported values. HBCD was not detected in 
the blood samples with the exception of one individual, where the concentration, 63 ng/kg, was 
well above the blank (Appendix). Because of the low concentration (below detection limits of 
LC/MS analysis), it was not possible to measure specific HBCD diastereomers in this sample. 
Analysis of the internal reference material (eel) and recovery standards in each of the four 
series indicated that the extraction and GC/MS analysis of the BFRs proceeded according to 
quality standards at the Netherlands Insitute for Fisheries Research.  
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5. Discussion 
Tetrabromobisphenol-A. Earlier studies published in the literature have reported TBBP-A to be 
detectable in humans [Klasson Wehler et al. 1997; Thomsen et al. 2001]. Investigating an 
occupationally exposed group, Jakobsson et al. [2002] quantified TBBP-A in four serum 
samples from Swedish computer technicians and reported TBBP-A concentrations between <1 
and 3.4 pmol/g lipid weight. The highest concentrations measured in whole blood in this current 
study are roughly a factor 10-20 higher than these values (after correction for the different 
units). In Norway, TBBP-A concentrations measured in a larger number of human blood plasma 
samples from different occupation groups were determined to be between 0.3 and 1.8 ng/g 
lipid [Thomsen et al. 2001].  
The differences between previous studies of plasma and serum and this study, using whole 
blood, may have to do with some difference in the distribution of TBBP-A among the different 
blood compartments.  
In a study of occupationally exposed workers in Sweden, Hagmar et al. [2000] estimated the 
halflife of TBBP-A in blood serum to be about 2 days. TBBP-A is known to be quickly 
metabolised in other mammals, such as the rat. One study showed that the half-life after oral 
administration in rat was <3 days [WHO/IPCS, 1995]. Rapid metabolism of TBBP-A has been 
reported in more recent studies in rats [Meerts et al. 1999] and quail [Halldin et al. 2001].  
A known possible metabolite of TBBP-A is tetrabromobisphenyl-A (Me-TBBP-A) [Hakk & Letcher 
2003]. This compound was also screened in the same GC/MS chromatograms generated for 
the other analytes, although none of this possible metabolite was detected in any samples 
above the level of blanks. Because this is more lipophilic than the parent compound, it probably 
would have a longer half-life in the body than the parent compound, and thus we suspect this is 
not a metabolic route in the individuals tested. Debromination is another possible metabolic 
pathway.  
 
Hexabromocyclododecane. HBCD has not been reported in human blood to date, therefore it 
was interesting to observe it in one individual in the current study (Table 1). HBCD has been 
found in human mother’s milk at concentrations between 250 and 2000 ng/kg lipids [Thomsen 
et al. 2003]. This is considerably higher than found in the current study, which can be at least 
party due to the higher lipid content in milk than whole blood. The higher lipid content means 
that the milk has a larger capacity to contain this lipophilic compound.   
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Exposure and Toxicology. What do these data mean from a toxicological standpoint? Levels 
of TBBP-A and HBCD were either undetectable or low in the blood of the individuals tested. The 
occupation of the blood donors does not belong to a high-risk category. The exposure for 
subjects in the current study was either low, or a high rate of elimination from the body must 
have been taking place. There are indications that TBBP-A can be eliminated quickly, as 
mentioned above.  
The higher TBBP-A levels in some individuals could also reflect different exposure scenarios, 
linked to geographical distribution of the chemical’s applications and usage. Information such as 
country of residence of the blood donors with higher TBBP-A concentrations in blood would give 
more insight into such possible correlations. Because the main uptake route for TBBP-A is 
probably inhalation [Sjodin et al. 2003], the type of diet in this case may not be correlated to 
TBBP-A levels in blood. BFR concentrations are also believed to be independent of age of the 
adult e.g. [Thomsen et al. 2002].  
The toxicology of these chemicals is not yet sufficiently elucidated. Legler & Brouwer [2003] 
have reviewed the literature for evidence of endocrine disruption of TBBP-A. While it is 
sometimes suggested that TBBP-A may act as an endocrine disruptor (at least in vitro), a 
cytotoxicant and an immunotoxicant, there is currently somewhat more evidence that it disrupts 
thyroid system functioning [Birnbaum & Staskal 2004] as for example was demonstrated in two 
recent articles [Meerts et al. 2000; Kitamura et al. 2002].  
The WWF’s Chemicals Check-up Project is one of the few studies to date to present data on the 
levels of TBBP-A or HBCD in human blood. 
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6. Conclusion 
TBBP-A was detected in 26 out of 40 human blood samples in the range of 2 - 330 ng/kg whole 
blood. These levels were higher compared to earlier reports from Sweden and Norway, but 
differences may be due to lower TBBP-A levels present in serum and plasma, sampled in those 
studies, compared to whole blood. 
TBBP-A is most likely less persistent than other BFRs (such as PBDEs), or PCBs. The TBBP-A 
concentrations found may be the result of exposure in the days before the sampling of the 
blood. 
HBCD was found in only one blood sample at a concentration of 63 ng/kg whole blood. 
However, this HBCD value is the first positive HBCD value in human blood ever reported. 
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Excel file with concentration data for TBBP-A and HBCD 
 
 
 
